• search hit 17 of 24
Back to Result List

Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality

  • Pioglitazone is an antidiabetic drug known to decrease peripheral, hepatic and vascular insulin resistance by the stimulation of PPARγ. In clinical trials, pioglitazone as monotherapy or in combination with other oral antidiabetic drugs or insulin has demonstrated to effectively improve blood glucose levels, long-term glucose control and the lipid profile. The vascular effects of pioglitazone include improvement of endothelial function and microcirculation, reduction of blood pressure and inflammatory surrogate markers of atherosclerosis, and a reduction of a composite measure of macrovascular events (death, stroke and myocardial infarctions). The drug is well tolerated and has an acceptable side effect profile. Because of its additional microvascular and macrovascular effects, pioglitazone is an attractive and effective treatment option for the management of Type 2 diabetes mellitus.

Export metadata

Additional Services

Share in Twitter Search Google Scholar Availability
Metadaten
Document Type:Article
Language:English
Author:Andreas Pfützner, Thomas Forst
Parent Title (English):Expert Opin Pharmacother. (Expert Opinion on Pharmacotherapy)
Volume:7
Issue:4
First Page:463
Last Page:476
ISSN:1465-6566
DOI:https://doi.org/10.1517/14656566.7.4.463
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=16503818
Publisher:Taylor & Francis
Date of first publication:2006/02/27
Tag:cardiovascular disease; insulin resistance; pioglitazone; thiazolidinediones; type 2 diabetes mellitus
Departments, institutes and facilities:Fachbereich Angewandte Naturwissenschaften
Dewey Decimal Classification (DDC):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Entry in this database:2015/04/02